SAN FRANCISCO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Wednesday, December 3, 2025 at 12:55 p.m. ET. Live webcasts and recordings of these presentations will be availa ...

Core Insights - Olema Pharmaceuticals, Inc. has successfully closed an underwritten public offering of 11,500,000 shares of common stock at a price of $19.00 per share, generating gross proceeds of approximately $218.5 million before expenses [1]. Company Overview - Olema Oncology is a clinical-stage biopharmaceutical company focused on developing targeted therapies for breast cancer and other endocrine-driven cancers. The company is advancing a pipeline that includes its lead product candidate, palazestrant (OP-1250), which is currently in two Phase 3 clinical trials, and OP-3136, a KAT6 inhibitor in Phase 1 clinical study [5].

Core Viewpoint - Olema Pharmaceuticals (OLMA) shares experienced a significant increase following Roche's positive clinical results for its breast cancer drug giredestrant, indicating a strong market potential for oral SERDs in hormone-driven breast cancer treatment [1][3]. Company Developments - Olema's stock price nearly tripled on November 18, closing up 136% after Roche's announcement, and continued to rise in subsequent trading [1]. - The company's lead candidate, palazestrant, is an oral SERD targeting breast cancer, similar to Roche's giredestrant, which has shown promising results [3][4]. Market Potential - The success of Roche's giredestrant validates the oral SERD class, enhancing confidence in Olema's pipeline and positioning palazestrant as a viable contender in a multibillion-dollar market [4][6]. - Oppenheimer's analyst Matthew Biegler increased the probability of palazestrant's success from 50% to 75% following Roche's data, reflecting a more optimistic outlook for Olema [6]. Analyst Ratings - Biegler maintained an "Outperform" rating on Olema and raised the price target to $45, suggesting a potential upside of 105% from current levels [6]. - The consensus rating for OLMA stock is currently "Strong Buy," with a mean target of approximately $24, indicating a potential upside of about 9% [9].

Core Insights - The article emphasizes the importance of staying updated on stocks within the biotech, pharma, and healthcare sectors, highlighting key trends and catalysts that influence market valuations [1]. Group 1: Industry Overview - The biotech, pharma, and healthcare industries are experiencing significant movements, and understanding these dynamics is crucial for investors [1]. - The article suggests subscribing to a weekly newsletter that provides insights into catalysts for investment decisions, including buy and sell ratings [1]. Group 2: Analyst Background - Edmund Ingham, a biotech consultant with over 5 years of experience, has compiled detailed reports on more than 1,000 companies in the sector [1]. - Ingham leads the Haggerston BioHealth investing group, which caters to both novice and experienced investors by offering forecasts and financial analyses [1].

Core Viewpoint - The positive results from Roche's oral SERD drug giredestrant in the lidERA trial have significantly boosted the stock of Olema Pharmaceuticals, indicating a de-risking effect for the entire SERD sector and positioning Olema's core asset, Palazestrant, as a leading candidate in breast cancer treatment [1][2][21]. Summary by Sections Roche's Giredestrant Trial Results - Roche announced that its oral SERD drug giredestrant achieved positive results in the lidERA study, marking the second Phase III positive data following the evERA trial at ESMO 2025 [2]. - The lidERA study involved over 4,100 patients and demonstrated statistically significant and clinically meaningful improvements in invasive disease-free survival compared to standard endocrine therapy for early-stage ER+/HER2- breast cancer patients [2][3]. Palazestrant's Mechanism and Development - Palazestrant, Olema's leading candidate, is a novel oral complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD) designed to inhibit estrogen receptor signaling and promote cancer cell degradation [4][5]. - Palazestrant's dual mechanism targets the root of resistance in breast cancer, offering a more effective treatment option compared to traditional SERDs [11][12]. Clinical Data and Future Prospects - Clinical data from ESMO 2025 showed that Palazestrant, in combination with ribociclib, achieved a median progression-free survival (PFS) of 15.5 months across all patients, with specific subgroups showing promising results [14][15][16]. - Palazestrant is currently undergoing two critical Phase III trials, with initial results expected in late 2026, which could pave the way for FDA submission and commercialization [8][9]. Industry Implications - The advancements in oral SERD therapies, particularly with Roche and Olema's developments, signify a paradigm shift in breast cancer treatment, moving towards more convenient and effective options for patients [20]. - The market is recognizing the value of Palazestrant, with potential peak sales estimated between $2.5 billion to $5 billion, indicating a significant opportunity for Olema in the competitive landscape of breast cancer therapies [17][21].

Core Points - Olema Pharmaceuticals, Inc. has announced a public offering of 10,000,000 shares of its common stock priced at $19.00 per share [1] - The gross proceeds from the offering are expected to be approximately $190.0 million before deductions [2] - The offering is expected to close on November 20, 2025, subject to customary closing conditions [2] Company Overview - Olema Oncology is a clinical-stage biopharmaceutical company focused on targeted therapies for breast cancer and other conditions [1] - The company is advancing a pipeline of novel therapies, including its lead product candidate, palazestrant (OP-1250), which is currently in two Phase 3 clinical trials [6] - Olema is also developing OP-3136, a potent lysine acetyltransferase 6 (KAT6) inhibitor, which is in a Phase 1 clinical study [6]

Summary of Olema Pharmaceuticals Conference Call Company Overview - **Company**: Olema Pharmaceuticals - **Focus**: Development of treatment options for breast cancer, specifically targeting estrogen receptor positive, HER2 negative breast cancer, which constitutes about 70% of breast cancer cases [3][4] Lead Asset - **Lead Molecule**: Palazestrant - **Mechanism**: Complete estrogen receptor antagonist, effectively shutting down growth signals [3] - **Clinical Trials**: - **OPERA-01**: Phase 3 trial for second/third-line treatment, readout expected in late 2026 [4] - **OPERA-02**: Phase 3 trial for first-line metastatic treatment in combination with ribociclib, readout expected in late 2028 [4][5] - **OP3136**: KAT6 inhibitor in Phase 1 trials for breast cancer, prostate cancer, and non-small cell lung cancer [5] Industry Context - **Market Size**: - Current global market for CDK4/6 inhibitors is approximately $15 billion, expected to grow to $15 billion-$20 billion by 2030 [20] - First-line breast cancer treatment market estimated at $10 billion-$15 billion, with second/third-line market at about $5 billion in the U.S. [34] Competitive Landscape - **Roche's LIDARA Trial**: Positive interim results reported, indicating improved disease-free survival with giredestrant [9][10] - **Comparison with Roche**: Olema's palazestrant shows better progression-free survival (PFS) in both ESR1 mutant and wild type populations compared to Roche's data [12][21] Key Findings from Recent Data - **ESMO Presentation**: Olema's phase 2 data showed approximately 10 months PFS in ESR1 wild type, compared to 5.5 months in Roche's control arm [12] - **Regulatory Considerations**: OPERA-01 and OPERA-02 trials are designed to separately analyze ESR1 mutant and wild type populations, enhancing regulatory clarity [24][26] Collaborations - **Novartis**: Collaboration for ribociclib supply in OPERA-02 trial [29] - **Pfizer**: Collaboration for atirmociclib, aiming to explore next-generation endocrine therapies [30][32] Future Expectations - **Upcoming Data**: Phase 1 data for OP3136 expected in the first half of 2026, focusing on safety and preliminary efficacy [41] - **Potential Indications**: Besides breast cancer, OP3136 is being explored for prostate cancer and non-small cell lung cancer, with preclinical activity observed [42][43] Conclusion - Olema Pharmaceuticals is positioned to capitalize on significant market opportunities in breast cancer treatment, with promising clinical data and strategic collaborations enhancing its competitive edge in the industry [20][34]

Company Overview - Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on targeted therapies for breast cancer and other conditions [1][5] - The company is advancing a pipeline of novel therapies, including its lead product candidate, palazestrant (OP-1250), which is currently in two Phase 3 clinical trials [5] Public Offering Announcement - Olema announced plans to commence a public offering of its common stock, which may include pre-funded warrants for certain investors [1] - The offering is subject to market conditions and will be managed by TD Cowen as the book-running manager [2] Offering Details - The proposed offering includes a 30-day option for underwriters to purchase up to an additional 15% of the total number of shares being offered [2] - The offering is made pursuant to a shelf registration statement filed with the SEC on January 6, 2025, and declared effective on January 15, 2025 [3]

Core Insights - Olema Pharmaceuticals, Inc. (OLMA) shares experienced a significant surge of 142.25 percent, reaching $20.64 in trading on Tuesday, with an increase of $12.12 despite the absence of new company-specific news [1] Stock Performance - The stock opened at $26.45, a notable rise from the previous close of $8.52 on the Nasdaq [1] - During the trading session, shares fluctuated between $18.11 and $27.17, with a substantial trading volume of 67,871,753, significantly higher than the average volume of 1,194,014 [1] - Over the past 52 weeks, Olema shares have seen a trading range between $2.86 and $27.17 [1]

Core Viewpoint - Olema Pharmaceuticals' stock surged significantly following positive phase 3 results from Roche's giredestrant study for early-stage breast cancer, indicating strong market interest and potential in the SERD drug sector [1][3]. Stock Performance - Olema Pharmaceuticals shares increased by 136.8%, reaching $20.17 during midday trading on Tuesday [3]. - The stock's rise was in stark contrast to Martin Shkreli's short position declaration, which suggested skepticism about Olema's valuation [1][2]. Analyst Ratings and Price Targets - HC Wainwright & Co. analyst Emily Bodnar maintained a Buy rating and raised the price target from $28 to $36 [4]. - Oppenheimer analyst Matthew Biegler kept an Outperform rating and increased the price target from $22 to $45 [4]. - JPMorgan maintained an Overweight rating and raised the price target from $29 to $32 [4]. Market Context - Shkreli criticized the overcrowded SERD market, implying that Olema's high valuation was unwarranted, yet the stock's performance suggests a differing market sentiment [2][3].